Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report by Ross Sadler, Mark Cook, Guy Pratt, Karthik Ramasamy, Ritika Rana, Mark Trehane Drayson, Doreen Zhu, Thomas Connor, Jennifer Helen Pinney

Get full text

Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma by Carmen Tsang, Joseph E. O’Reilly, Lewis Carpenter, Charles Duffield, Filipa Tunaru, Jamie Wallis, Alycia Perkins, Thomas Price, Sam Wood, Karthik Ramasamy

Get full text

The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service by Rakesh Popat, Supratik Basu, Sarah Henshaw, Kamaraj Karunanithi, Karthik Ramasamy, Inderjit Singh, Anish Tailor, Ian Walker, Tim Warren, Noreen Ali, Charles Duffield, Gordon Cook

Get full text

Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study by Dipal Mehta, Robert Cicero, Laura Chiecchio, Samir Asher, Martin Kaiser, Sarah Gooding, Kara‐Louise Royle, Catherine Olivier, Doina Levinte, Charlotte Kennaway, Karthik Ramasamy, Kwee Yong, Matthew Jenner

Get full text

Belantamab Mafodotin Monotherapy for Multiply‐Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland by Edmund C. R. Watson, Faouzi Djebbari, Fotios Panitsas, Grant Vallance, Samir Asher, Malahat Saeed, Mairi Walker, Matthew Powell, Alexandros Rampotas, Heather Leary, Akhil Khera, Angharad Atkinson, Ni Ni Aung, Gillian Brearton, Joseph Froggatt, Ezzat El Hassadi, Ellen Gokkel, Sarah Lawless, Beena Salhan, Salim Shafeek, Anand Lokare, Carol Stirling, Udo Oppermann, Richard Soutar, Rakesh Popat, Charalampia Kyriakou, Karthik Ramasamy

Get full text